Cardiac oxidative stress in diabetes: Mechanisms and therapeutic potential

Pharmacology and Therapeutics

Volumn 172, Issue , 2017, Pages 50-62

  Faria, Alyssa ^a   Persaud, Shanta J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Diabetic cardiomyopathy; Hyperglycaemia; Oxidative stress; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIOXIDANT; ARACHIDONATE 15 LIPOXYGENASE; CURCUMIN; DIACYLGLYCEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; NOBILETIN; PEROXIREDOXIN 3; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RUTOSIDE; SITAGLIPTIN; SULFITE REDUCTASE (NADPH); UBIDECARENONE; XANTHINE OXIDASE; ADVANCED GLYCATION END PRODUCT;

DIABETIC CARDIOMYOPATHY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXERCISE; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHIES; HYPERGLYCEMIA; METABOLISM; PATHOPHYSIOLOGY;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; OXIDATIVE STRESS; PROTEIN KINASE C; REACTIVE OXYGEN SPECIES;

EID: 85007448569     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.11.013     Document Type: Review

References (90)

1. Al-Rasheed, N.M., Al-Rasheed, N.M., Hasan, I.H., Al-Amin, M.A., Al-Ajmi, H.N., Mahmoud, A.M., Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats. Drug Design, Development and Therapy 10 (2016), 2095–2107.
2. Amado, L.C., Saliaris, A.P., Raju, S.V., Lehrke, S., John, M.S., Xie, J., et al. Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure. Journal of Molecular and Cellular Cardiology 39:3 (2005), 531–536.
3. Anker, S.D., Doehner, W., Rauchhaus, M., Sharma, R., Francis, D., Knosalla, C., et al. Uric acid and survival in chronic heart failure: Validation and application in metabolic, functional, and hemodynamic staging. Circulation 107:15 (2003), 1991–1997.
4. Arkat, S., Umbarkar, P., Singh, S., Sitasawad, S.L., Mitochondrial Peroxiredoxin-3 protects against hyperglycemia induced myocardial damage in diabetic cardiomyopathy. Free Radical Biology and Medicine 97 (2016), 489–500.
5. Ashrafi, R., Davis, G., Cardiomyopathy in diabetics: A review of current opinion on the underlying pathological mechanisms. Avances en Diabetología 27:5 (2011), 175–181.
6. Bidasee, K.R., Zheng, H., Shao, C.H., Parbhu, S.K., Rozanski, G.J., Patel, K.P., Exercise training initiated after the onset of diabetes preserves myocardial function: Effects on expression of β-adrenoceptors. Journal of Applied Physiology 105:3 (2008), 907–914.
7. Boudina, S., Abel, E.D., Diabetic cardiomyopathy, causes and effects. Reviews in Endocrine & Metabolic Disorders 11:1 (2010), 31–39.
8. 2 +-sensitive isoforms in the failing human heart. Circulation 99:3 (1999), 384–391.
9. Bowman, J.C., Steinberg, S.F., Jiang, T., Geenen, D.L., Fishman, G.I., Buttrick, P.M., Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. The Journal of Clinical Investigation 100:9 (1997), 2189–2195.
10. Brand, M.D., Affourtit, C., Esteves, T.C., Green, K., Lambert, A.J., Miwa, S., et al. Mitochondrial superoxide: Production, biological effects, and activation of uncoupling proteins. Free Radical Biology and Medicine 37:6 (2004), 755–767.
11. Brownlee, M., Biochemistry and molecular cell biology of diabetic complications. Nature 414:6865 (2001), 813–820.
12. Brownlee, M., The pathobiology of diabetic complications: A unifying mechanism. Diabetes 54:6 (2005), 1615–1625.
13. Cailleret, M., Amadou, A., Andrieu-Abadie, N., Nawrocki, A., Adamy, C., Ait-Mamar, B., Pecker, F., N-acetylcysteine prevents the deleterious effect of tumor necrosis factor-α on calcium transients and contraction in adult rat cardiomyocytes. Circulation 109:3 (2014), 406–411.
14. Chawla, D., Bansal, S., Banerjee, B.D., Madhu, S.V., Kalra, O.P., Tripathi, A.K., Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications. Microvascular Research 95 (2014), 1–6.
15. Chen, L., Magliano, D.J., Zimmet, P.Z., The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nature Reviews Endocrinology 8:4 (2012), 228–236.
16. Christ, S.E., Moffitt, A.J., Peck, D., White, D.A., The effects of tetrahydrobiopterin (BH4) treatment on brain function in individuals with phenylketonuria. Neurologic Clinics 3 (2013), 539–547.
17. Cortés-Jofré, M., Rueda, J.R., Corsini-Muñoz, G., Fonseca-Cortés, C., Caraballoso, M., Bonfill Cosp, X., Drugs for preventing lung cancer in healthy people. Cochrane Database of Systematic Reviews(10), 2012, CD002141.
18. Bjelakovic, G., Nikolova, D., Gluud, L.L., Simonetti, R.G., Gluud, C., Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: Systematic review and meta-analysis. JAMA 297:8 (2007), 842–857.
19. Coughlan, M.T., Thorburn, D.R., Penfold, S.A., Laskowski, A., Harcourt, B.E., Sourris, K.C., et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. Journal of the American Society of Nephrology 20:4 (2009), 742–752.
20. Crabtree, M.J., Hale, A.B., Channon, K.M., Dihydrofolate reductase protects endothelial nitric oxide synthase from uncoupling in tetrahydrobiopterin deficiency. Free Radical Biology and Medicine 50:11 (2011), 1639–1646.
21. Das, A.K., Das, J.P., Chandrasekar, S., Specific heart muscle disease in diabetes mellitus—A functional structural correlation. International Journal of Cardiology 17:3 (1987), 299–302.
22. Eguchi, K., Boden-Albala, B., Jin, Z., Rundek, T., Sacco, R.L., Homma, S., et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. The American Journal of Cardiology 101:12 (2008), 1787–1791.
23. Feng, Q., Lu, X., Jones, D.L., Shen, J., Arnold, J.M., Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 104:6 (2001), 700–704.
24. Finkelstein, E., Rosen, G.M., Rauckman, E.J., Spin trapping of superoxide and hydroxyl radical: Practical aspects. Archives of Biochemistry and Biophysics 200:1 (1980), 1–16.
25. Fowler, M.J., Microvascular and macrovascular complications of diabetes. Clinical Diabetes 26:2 (2008), 77–82.
26. Fox, C.S., Coady, S., Sorlie, P.D., D'Agostino, R.B.S., Pencina, M.J., Vasan, R.S., et al. Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham heart study. Circulation 115:12 (2007), 1544–1550.
27. Giulivi, C., Boveris, A., Cadenas, E., Hydroxyl radical generation during mitochondrial electron-transfer and the formation of 8-hydroxydesoxyguanosine in mitochondrial-DNA. Archives of Biochemistry and Biophysics 316:2 (1995), 909–916.
28. Gray, S.P., Di Marco, E., Kennedy, K., Chew, P., Okabe, J., El-Osta, A., et al. Reactive oxygen species can provide Atheroprotection via NOX4-dependent inhibition of inflammation and vascular remodeling. Arteriosclerosis, Thrombosis, and Vascular Biology 36:2 (2016), 295–307.
29. Guo, Z., Xia, Z., Jiang, J., McNeill, J.H., Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine. The American Journal of Physiology - Heart and Circulatory Physiology 292:4 (2007), H1728–H1736.
30. Halestrap, A.P., What is the mitochondrial permeability transition pore?. Journal of Molecular and Cellular Cardiology 46:6 (2009), 821–831.
31. Hao, G., Dong, Y., Huo, R., Wen, K., Zhang, Y., Liang, G., Rutin inhibits neuroinflammation and provides neuroprotection in an experimental rat model of subarachnoid hemorrhage, possibly through suppressing the RAGE–NF-κB inflammatory signaling pathway. Neurochemical Research 41:6 (2016), 1496–1504.
32. Hare, J.M., Mangal, B., Brown, J., Fisher, C., Freudenberger, R., Colucci, W.S., et al. Impact of oxypurinol in patients with symptomatic heart failure: Results of the OPT-CHF study. Journal of the American College of Cardiology 51:24 (2008), 2301–2309.
33. Harzand, A., Tamariz, L., Hare, J.M., Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. Congestive Heart Failure 18:3 (2012), 179–182.
34. Heger, J., Godecke, A., Flogel, U., Merx, M.W., Molojavyi, A., Kuhn-Velten, W.N., et al. Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circulation Research 90:1 (2002), 93–99.
35. Hingtgen, S.D., Tian, X., Yang, J., Dunlay, S.M., Peek, A.S., Wu, Y., Davisson, R.L., Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy. Physiological Genomics 26:3 (2006), 180–191.
36. Ho, M.J., Li, E.C., Wright, J.M., Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database of Systematic Reviews, 3, 2016, CD007435.
37. Hou, J., Zheng, D., Fung, G., Deng, H., Chen, L., Liang, J., Hu, Y., Mangiferin suppressed advanced glycation end products (AGEs) through NF-κB deactivation and displayed anti-inflammatory effects in streptozotocin and high fat diet-diabetic cardiomyopathy rats. Canadian Journal of Physiology and Pharmacology 94:3 (2016), 332–340.
38. Huynh, K., Kiriazis, H., Du, X., Love, J., Jandeleit-Dahm, K., Forbes, J., et al. Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. Diabetologia 55:5 (2012), 1544–1553.
39. Ide, T., Tsutsui, H., Kinugawa, S., Utsumi, H., Kang, D., Hattori, N., et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circulation Research 85:4 (1999), 357–363.
40. IDF Diabetes Atlas, 7th Edition. http://www.diabetesatlas.org/.
41. Janssens, S., Pokreisz, P., Schoonjans, L., Pellens, M., Vermeersch, P., Tjwa, M., et al. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation Research 94:9 (2004), 1256–1262.
42. Jo, H., Otani, H., Jo, F., Shimazu, T., Okazaki, T., Yoshioka, K., et al. Inhibition of nitric oxide synthase uncoupling by sepiapterin improves left ventricular function in streptozotocin-induced diabetic mice. Clinical and Experimental Pharmacology & Physiology 38:8 (2011), 485–493.
43. Kannel, W.B., McGee, D.L., Diabetes and cardiovascular disease: The Framingham study. JAMA 241:19 (1979), 2035–2038.
44. Kayama, Y., Raaz, U., Jagger, A., Adam, M., Schellinger, I.N., Sakamoto, M., et al. Diabetic cardiovascular disease induced by oxidative stress. International Journal of Molecular Sciences 16:10 (2015), 25234–25263.
45. Koncsos, G., Varga, Z.V., Baranyai, T., Boengler, K., Rohrbach, S., Li, L., Mátyás, C., Diastolic dysfunction in prediabetic male rats: Role of mitochondrial oxidative stress. American Journal of Physiology - Heart and Circulatory Physiology 311:4 (2016), H927–H943.
46. Kowluru, R.A., Mishra, M., Oxidative stress, mitochondrial damage and diabetic retinopathy. Biochimica et Biophysica Acta-Molecular Basis of Disease 1852:11 (2015), 2474–2483.
47. Kuroda, J., Ago, T., Matsushima, S., Zhai, P., Schneider, M.D., Sadoshima, J., NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proceedings of the National Academy of Sciences of the United States of America 107:35 (2010), 15565–15570.
48. Li, J.M., Gall, N.P., Grieve, D.J., Chen, M., Shah, A.M., Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40:4 (2002), 477–484.
49. Liu, X., Gan, W., Zou, Y., Yang, B., Su, Z., Deng, J., et al. Elevated levels of urinary markers of oxidative DNA and RNA damage in type 2 diabetes with complications. Oxidative Medicine and Cellular Longevity, 2016, 2016, 4323198.
50. Liu, C., Lu, X.Z., Shen, M.Z., Xing, C.Y., Ma, J., Duan, Y.Y., Yuan, L.J., N-acetyl cysteine improves the diabetic cardiac function: Possible role of fibrosis inhibition. BMC Cardiovascular Disorders, 15, 2015, 84.
51. Malik, S., Bhatia, J., Suchal, K., Gamad, N., Dinda, A.K., Gupta, Y.K., Arya, D.S., Nobiletin ameliorates cisplatin-induced acute kidney injury due to its anti-oxidant, anti-inflammatory and anti-apoptotic effects. Experimental and Toxicologic Pathology 67:7 (2015), 427–433.
52. Miki, T., Yuda, S., Kouzu, H., Miura, T., Diabetic cardiomyopathy: Pathophysiology and clinical features. Heart Failure Reviews 18:2 (2013), 149–166.
53. Mortensen, S.A., Rosenfeldt, F., Kumar, A., Dolliner, P., Filipiak, K.J., Pella, D., Q-SYMBIO Study Investigators, The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: Results from Q-SYMBIO: A randomized double-blind trial. JACC Heart Failure 2:6 (2014), 641–649.
54. Na, L., Zhang, Q., Jiang, S., Du, S., Zhang, W., Li, Y., Niu, Y., Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: A double-blind randomized controlled trial. Scientific Reports, 5, 2015, 10344.
55. Nakamura, K., Fushimi, K., Kouchi, H., Mihara, K., Miyazaki, M., Ohe, T., et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 98:8 (1998), 794–799.
56. Ni, R., Cao, T., Xiong, S., Ma, J., Fan, G., Lacefield, J.C., et al. Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy. Free Radical Biology and Medicine 90 (2016), 12–23.
57. Nishikawa, T., Edelstein, D., Du, X.L., Yamagishi, S., Matsumura, T., Kaneda, Y., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:6779 (2000), 787–790.
58. Pastori, D., Pignatelli, P., Farcomeni, A., Menichelli, D., Nocella, C., Carnevale, R., Violi, F., Aging-related decline of glutathione peroxidase 3 and risk of cardiovascular events in patients with atrial fibrillation. Journal of the American Heart Association, 5(9), 2016, e003682.
59. Picatoste, B., Ramírez, E., Caro-Vadillo, A., Iborra, C., Egido, J., Tuñón, J., Lorenzo, Ó., Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PloS One, 8(10), 2013, e78330.
60. Pickup, J.C., Chusney, G.D., Thomas, S.M., Burt, D., Plasma interleukin-6, tumour necrosis factor α and blood cytokine production in type 2 diabetes. Life Sciences 67:3 (2000), 291–300.
61. Ray, R., Murdoch, C.E., Wang, M., Santos, C.X., Zhang, M., Alom-Ruiz, S., Shah, A.M., Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arteriosclerosis, Thrombosis, and Vascular Biology 31 (2011), 1368–1376.
62. Rubler, S., Dlugash, J., Yuceoglu, Z.Y., Kumral, T., Branwood, A.W., Grishman, A., New type of cardiomyopathy associated with diabetic glomerulosclerosis. The American Journal of Cardiology 30 (1972), 595–602.
63. Sahebkar, A., Cicero, A.F., Simental-Mendía, L.E., Aggarwal, B.B., Gupta, S.C., Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research 107 (2016), 234–242.
64. Saklani, R., Gupta, S.K., Mohanty, I.R., Kumar, B., Srivastava, S., Mathur, R., Cardioprotective effects of rutin via alteration in TNF-α, CRP, and BNP levels coupled with antioxidant effect in STZ-induced diabetic rats. Molecular and Cellular Biochemistry 420:1–2 (2016), 65–72.
65. Schroder, K., Zhang, M., Benkhoff, S., Mieth, A., Pliquett, R., Kosowski, J., Brandes, R.P., Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circulation Research 110:9 (2012), 1217–1225.
66. Segal, B.H., Grimm, M.J., Khan, A.N.H., Han, W., Blackwell, T.S., Regulation of innate immunity by NADPH oxidase. Free Radical Biology and Medicine 53:1 (2012), 72–80.
67. Serban, M.C., Sahebkar, A., Zanchetti, A., Mikhailidis, D.P., Howard, G., Antal, D., Banach, M., Lipid and blood pressure meta-analysis collaboration (LBPMC) group. Effects of quercetin on blood pressure: A systematic review and meta-analysis of randomized controlled trials. Journal of the American Heart Association, 5(7), 2016 (pii:e002713).
68. Sharma, N.M., Rabeler, B., Zheng, H., Raichlin, E., Patel, K.P., Exercise training attenuates upregulation of p47phox and p67phox in hearts of diabetic rats. Oxidative Medicine and Cellular Longevity, 2016, 2016, 5868913.
69. Shaw, J.E., Sicree, R.A., Zimmet, P.Z., Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 87:1 (2010), 4–14.
70. Shehzad, A., Ha, T., Subhan, F., Lee, Y.S., New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. European Journal of Nutrition 50:3 (2011), 151–161.
71. Shen, E., Li, Y., Li, Y., Shan, L., Zhu, H., Feng, Q., et al. Rac1 is required for cardiomyocyte apoptosis during hyperglycemia. Diabetes 58:10 (2009), 2386–2395.
72. Shiba, T., Inoguchi, T., Sportsman, J.R., Heath, W.F., Bursell, S., King, G.L., Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. The American Journal of Physiology 265:5 Pt 1 (1993), E783–E793.
73. Soebiyanto, R.P., Sreenath, S.N., Qu, C.K., Loparo, K.A., Bunting, K.D., Complex systems biology approach to understanding coordination of JAK-STAT signaling. Bio Systems 90:3 (2007), 830–842, Dec 31.
74. Stadtman, E.R., Protein oxidation and aging. Science 257:5074 (1992), 1220–1224.
75. Stamler, J., Vaccaro, O., Neaton, J.D., Wentworth, D., Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16:2 (1993), 434–444.
76. Suzuki, H., Kayama, Y., Sakamoto, M., Iuchi, H., Shimizu, I., Yoshino, T., et al. Arachidonate 12/15-lipoxygenase-induced inflammation and oxidative stress are involved in the development of diabetic cardiomyopathy. Diabetes 64:2 (2015), 618–630.
77. Szakmany, T., Hauser, B., Radermacher, P., N-acetylcysteine for sepsis and systemic inflammatory response in adults. Cochrane Database of Systematic Reviews, 9, 2012, CD006616.
78. Taylor-Fishwick, D.A., Weaver, J., Glenn, L., Kuhn, N., Rai, G., Jadhav, A., et al. Selective inhibition of 12-lipoxygenase protects islets and beta cells from inflammatory cytokine-mediated beta cell dysfunction. Diabetologia 58:3 (2015), 549–557.
79. 2 emission under energy/redox stress leads to myocardial dysfunction during type I diabetes. Clinical Science (London, England) 129:7 (2015), 561–574.
80. Uribarri, J., Cai, W., Peppa, M., Goodman, S., Ferrucci, L., Striker, G., et al. Circulating glycotoxins and dietary advanced glycation endproducts: Two links to inflammatory response, oxidative stress, and aging. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 62:4 (2007), 427–433.
81. Valko, M., Leibfritz, D., Moncol, J., Cronin, M.T., Mazur, M., Telser, J., Free radicals and antioxidants in normal physiological functions and human disease. The International Journal of Biochemistry & Cell Biology 39:1 (2007), 44–84.
82. Wakasaki, H., Koya, D., Schoen, F.J., Jirousek, M.R., Ways, D.K., Hoit, B.D., et al. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America 94:17 (1997), 9320–9325.
83. Wautier, M.P., Chappey, O., Corda, S., Stern, D.M., Schmidt, A.M., Wautier, J.L., Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. American Journal of Physiology. Endocrinology and Metabolism 280:5 (2001), E685–E694.
84. Way, K.J., Isshiki, K., Suzuma, K., Yokota, T., Zvagelsky, D., Schoen, F.J., et al. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 51:9 (2002), 2709–2718.
85. Westermann, D., Van Linthout, S., Dhayat, S., Dhayat, N., Schmidt, A., Noutsias, M., et al. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Research in Cardiology 102:6 (2007), 500–507.
86. Wu, H.E., Baumgardt, S.L., Fang, J., Paterson, M., Liu, Y., Du, J., Kersten, J.R., Cardiomyocyte GTP cyclohydrolase 1 protects the heart against diabetic cardiomyopathy. Scientific Reports, 6, 2016, 27925.
87. Yamagishi, S.I., Fukami, K., Matsui, T., Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovascular Diabetology, 14, 2015, 2, 10.1186/s12933-015-0176-5.
88. Yu, W., Wu, J., Cai, F., Xiang, J., Zha, W., Fan, D., Liu, C., Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats. PloS One, 7(12), 2012, e52013.
89. Zhang, N., Yang, Z., Xiang, S.Z., Jin, Y.G., Wei, W.Y., Bian, Z.Y., Tang, Q.Z., Nobiletin attenuates cardiac dysfunction, oxidative stress, and inflammatory in streptozotocin: Induced diabetic cardiomyopathy. Molecular and Cellular Biochemistry 417:1–2 (2016), 87–96.
90. Zimmet, P., Alberti, K., Shaw, J., Global and societal implications of the diabetes epidemic. Nature 414:6865 (2001), 782–787.